NAD+ Research Overview

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, where it participates in fundamental biological processes ranging from energy metabolism to gene expression regulation. Discovered in the early twentieth century during investigations into cellular fermentation, NAD+ has since become one of the most extensively studied molecules in biochemistry, with research interest expanding in recent decades to include its roles in cellular aging, DNA maintenance, and metabolic signaling.

NAD+ exists in two interconvertible redox forms: the oxidized form (NAD+) and the reduced form (NADH). This redox pair is central to energy metabolism, particularly in the mitochondrial electron transport chain, where NADH donates electrons to drive ATP synthesis. The molecule also serves as a direct substrate for several families of enzymes that use it as a signaling currency rather than a redox cofactor.

This article is educational and intended for researchers studying NAD+ biology and its broader metabolic roles. It does not constitute medical advice.

Sirtuins: NAD+-Dependent Gene Regulation

Sirtuins (SIRT1 through SIRT7) form a conserved family of NAD+-dependent protein deacylases that regulate gene expression, stress responses, mitochondrial function, and genome stability. Each sirtuin consumes one molecule of NAD+ per catalytic cycle, cleaving the glycosidic bond to release nicotinamide and using the remaining ADP-ribose fragment for deacylation reactions. This coupling means sirtuin activity is directly proportional to available NAD+.

In mammalian biology, SIRT1 is the most studied nuclear sirtuin, regulating targets including p53, NF-κB, and FOXO transcription factors relevant to cell survival and inflammatory gene programs. SIRT3 is the primary mitochondrial deacetylase, regulating enzymes of the tricarboxylic acid cycle and electron transport chain. SIRT6 plays a role in genomic stability and DNA double-strand break repair. The broad regulatory scope of the sirtuin family has made them central to NAD+ aging biology research (Verdin, 2015, Science, PMID 26785480).

PARP Enzymes and DNA Repair

Poly(ADP-ribose) polymerases (PARPs), particularly PARP1, are among the largest consumers of NAD+ in the cell. In response to DNA strand breaks, PARP1 is rapidly recruited to damage sites and uses NAD+ to synthesize poly(ADP-ribose) chains on histones and itself, opening chromatin and recruiting DNA repair machinery. Under conditions of high genotoxic or oxidative stress, PARP1 activation can consume NAD+ rapidly enough to deplete it to levels incompatible with sirtuin activity — creating a mechanistic competition between DNA repair and metabolic gene regulation (Alemasova and Lavrik, 2019, Nucleic Acids Research, PMID 30799503).

This PARP–sirtuin competition for NAD+ substrate is a core concept in aging biology research, since both DNA damage and oxidative stress accumulate with age, potentially driving a self-reinforcing cycle of NAD+ depletion.

CD38 and the NAD+ Consumption Landscape

CD38 is a multifunctional enzyme that functions as both an NAD+ glycohydrolase and ADP-ribose cyclase. Research using CD38 knockout mice identified it as the primary driver of the age-related decline in tissue NAD+ levels: CD38 expression and activity increase substantially with aging, and CD38-deficient mice maintain youthful tissue NAD+ concentrations and mitochondrial function well into old age. CD38 also degrades NMN — one of the key NAD+ biosynthesis intermediates — limiting its availability for the salvage pathway (Camacho-Pereira et al., 2016, Cell Metabolism, PMID 27304511).

Understanding CD38’s role as a dominant NAD+-consuming enzyme in aging tissue has opened research directions examining whether targeting CD38 can preserve the NAD+ pool in aged biological systems.

NAMPT and the NAD+ Salvage Pathway

The predominant route for NAD+ biosynthesis in most mammalian tissues is the salvage pathway, which recycles nicotinamide — a byproduct of sirtuin and PARP reactions — back into NAD+. NAMPT (nicotinamide phosphoribosyltransferase) catalyzes the first and rate-limiting step of this pathway: the conversion of nicotinamide to NMN. NMN is then converted to NAD+ by NMNAT enzymes present in different cellular compartments.

NAMPT activity declines with age across multiple tissues in both rodent models and humans, contributing directly to the age-associated fall in NAD+ levels. Researchers have explored the consequences of NAMPT downregulation and the effects of NAMPT activators as tools for sustaining NAD+ synthesis in aged tissues (Khaidizar et al., 2021, Int J Mol Sci, PMID 33918226).

NAD+ Decline in Aging: Mechanistic Research

A series of landmark preclinical studies established mechanistic connections between declining NAD+ and features of biological aging. Work from Sinclair’s laboratory demonstrated that in aging mouse muscle, reduced nuclear NAD+ caused HIF-1α accumulation under normal oxygen conditions — a pseudohypoxic state disrupting SIRT1-dependent nuclear-mitochondrial communication. Restoring NAD+ via NMN reversed this disruption and restored mitochondrial function within one week in a SIRT1-dependent manner (Gomes et al., 2013, Cell, PMID 24360282).

Earlier work from the Imai laboratory demonstrated that NAMPT-mediated NAD+ biosynthesis is severely compromised in metabolic organs under high-fat diet conditions and during normal aging. Oral NMN administration in mice restored NAD+ and SIRT1 activity in the liver, improving glucose tolerance and insulin sensitivity (Yoshino et al., 2011, Cell Metabolism, PMID 21982712). A subsequent 12-month chronic NMN administration study in aging mice confirmed long-term tolerability and documented suppression of age-associated body weight gain, enhanced energy metabolism, improved insulin sensitivity, and ameliorated eye function (Mills et al., 2016, Cell Metabolism, PMID 28068222).

Human Clinical Trial Evidence

The transition from preclinical to human investigation has accelerated since 2016. A foundational study from Brenner’s laboratory documented that oral nicotinamide riboside (NR) — an NAD+ precursor — is bioavailable in humans and dose-dependently raises blood NAD+ metabolites, with a single dose increasing NAD+ up to 2.7-fold. The study identified NAAD (nicotinic acid adenine dinucleotide) as a sensitive biomarker for effective NAD+ repletion in humans (Trammell et al., 2016, Nature Communications, PMID 27721479).

The first placebo-controlled crossover RCT of chronic NR supplementation in healthy middle-aged and older adults confirmed both tolerability and target engagement, with signals suggesting potential reductions in systolic blood pressure and arterial stiffness in participants with elevated vascular risk (Martens et al., 2018, Nature Communications, PMID 29599478). A 2021 RCT in postmenopausal prediabetic women found that oral NMN supplementation significantly increased skeletal muscle insulin sensitivity — measured directly by hyperinsulinemic-euglycemic clamp — with upregulation of AKT/mTOR phosphorylation and muscle remodeling gene expression in the treatment group (Yoshino et al., 2021, Science, PMID 33888596).

A meta-analysis pooling 40 clinical studies (N=14,750 participants) found that NAD+ precursor supplementation significantly reduced triglycerides, total cholesterol, and LDL while increasing HDL in humans, though it also raised fasting plasma glucose — a finding warranting careful consideration in metabolic research contexts. The meta-analysis included niacin (nicotinic acid), which has well-characterized lipid-modifying pharmacology distinct from NMN or NR; pooled lipid outcomes may not generalize to individual precursors (Zhong et al., 2022, Nutrition & Metabolism, PMID 35303905).

Neurological Research

NAD+ biology has become an active focus in neurodegeneration research. The NADPARK trial — a randomized double-blind Phase I trial in 30 newly diagnosed Parkinson’s patients — found that oral NR was well tolerated at the dose studied and significantly increased cerebral NAD+ levels as measured by ⁻¹P-MRS brain imaging. Participants achieving higher brain NAD+ showed altered cerebral metabolism , alongside upregulation of cellular maintenance genes and reduced inflammatory markers in serum and cerebrospinal fluid (Brakedal et al., 2022, Cell Metabolism, PMID 35235774). A subsequent Phase I safety trial confirmed that higher doses of NR were well tolerated in Parkinson’s patients and produced five-fold elevations in blood NAD+ (Berven et al., 2023, Nature Communications, PMID 38016950).

In experimental model systems, NMN-driven mitophagy stimulation has been studied in the context of amyloid-beta and tau pathology relevant to Alzheimer’s research. NAD+ supplementation was associated with reduced amyloid accumulation via microglial activity and reversal of tau hyperphosphorylation in C. elegans and cellular models, providing mechanistic support for NAD+ augmentation in neurodegeneration research (Fang et al., 2019, Nature Neuroscience, PMID 30742114). This neurological research area has thematic parallels with other mitochondrially targeted compounds studied in laboratory settings, including MOTS-c.

Current Evidence Status

A 2026 systematic review synthesizing 33 human intervention trials and 80 rodent studies concluded that oral NR and NMN consistently demonstrate biochemical target engagement — elevating NAD+ — and are well tolerated over weeks to months in human trials. In rodent models, NAD+ augmentation improved metabolic, mitochondrial, inflammatory, and functional outcomes with consistency. However, in human trials, effects on functional, metabolic, and vascular endpoints were heterogeneous and frequently endpoint-specific or null, leading the authors to conclude that clinical effectiveness for aging or wellness applications remains inconclusive pending larger, longer RCTs (Gallagher and Emmanuel, 2026, Ageing Research Reviews, PMID 41655607).

Research Supply

New Tech Science supplies NAD+ as a research reagent for qualified laboratory investigators. This product is for research use only and is not intended for human or animal consumption outside of formally regulated research protocols. Researchers should consult the primary scientific literature and applicable institutional guidelines when designing studies examining NAD+ biology.

This article is for educational and research discussion purposes only. It does not constitute medical advice, treatment recommendations, or endorsement of any specific application.

References

1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213. https://doi.org/10.1126/science.aac4854 (PMID 26785480)
2. Gomes AP, Price NL, Ling AJY, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. https://doi.org/10.1016/j.cell.2013.11.037 (PMID 24360282)
3. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism. 2011;14(4):528–536. https://doi.org/10.1016/j.cmet.2011.08.014 (PMID 21982712)
4. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139. https://doi.org/10.1016/j.cmet.2016.05.006 (PMID 27304511)
5. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795–806. https://doi.org/10.1016/j.cmet.2016.09.013 (PMID 28068222)
6. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016;7:12948. https://doi.org/10.1038/ncomms12948 (PMID 27721479)
7. Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Research. 2019;47(8):3811–3827. https://doi.org/10.1093/nar/gkz120 (PMID 30799503)
8. Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nature Neuroscience. 2019;22(3):401–412. https://doi.org/10.1038/s41593-018-0332-9 (PMID 30742114)
9. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. https://doi.org/10.1038/s41467-018-03421-7 (PMID 29599478)
10. Khaidizar FD, Bessho Y, Nakahata Y. Nicotinamide phosphoribosyltransferase as a key molecule of the aging/senescence process. International Journal of Molecular Sciences. 2021;22(7):3709. https://doi.org/10.3390/ijms22073709 (PMID 33918226)
11. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. https://doi.org/10.1126/science.abe9985 (PMID 33888596)
12. Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing. Mechanisms of Ageing and Development. 2021;199:111567. https://doi.org/10.1016/j.mad.2021.111567 (PMID 34517020)
13. Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism. 2022;34(3):396–407. https://doi.org/10.1016/j.cmet.2022.02.001 (PMID 35235774)
14. Zhong O, Wang J, Tan Y, Lei X, Tang Z. Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis. Nutrition & Metabolism. 2022;19:20. https://doi.org/10.1186/s12986-022-00653-9 (PMID 35303905)
15. Berven H, Kverneng S, Sheard E, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature Communications. 2023;14(1):7793. https://doi.org/10.1038/s41467-023-43514-6 (PMID 38016950)
16. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. https://doi.org/10.1016/j.arr.2026.103057 (PMID 41655607)